166 related articles for article (PubMed ID: 36434007)
1. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity.
Smith N; Possémé C; Bondet V; Sugrue J; Townsend L; Charbit B; Rouilly V; Saint-André V; Dott T; Pozo AR; Yatim N; Schwartz O; Cervantes-Gonzalez M; Ghosn J; Bastard P; Casanova JL; Szwebel TA; Terrier B; Conlon N; O'Farrelly C; Cheallaigh CN; Bourke NM; Duffy D
Nat Commun; 2022 Nov; 13(1):7254. PubMed ID: 36434007
[TBL] [Abstract][Full Text] [Related]
2. Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia.
Su HC; Jing H; Zhang Y; Casanova JL
Annu Rev Immunol; 2023 Apr; 41():561-585. PubMed ID: 37126418
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
[TBL] [Abstract][Full Text] [Related]
4. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies.
Akbil B; Meyer T; Stubbemann P; Thibeault C; Staudacher O; Niemeyer D; Jansen J; Mühlemann B; Doehn J; Tabeling C; Nusshag C; Hirzel C; Sanchez DS; Nieters A; Lother A; Duerschmied D; Schallner N; Lieberum JN; August D; Rieg S; Falcone V; Hengel H; Kölsch U; Unterwalder N; Hübner RH; Jones TC; Suttorp N; Drosten C; Warnatz K; Spinetti T; Schefold JC; Dörner T; Sander LE; Corman VM; Merle U; ; Kurth F; von Bernuth H; Meisel C; Goffinet C
J Clin Immunol; 2022 Aug; 42(6):1111-1129. PubMed ID: 35511314
[TBL] [Abstract][Full Text] [Related]
5. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1.
Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
[TBL] [Abstract][Full Text] [Related]
7. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Matuozzo D; Talouarn E; Marchal A; Zhang P; Manry J; Seeleuthner Y; Zhang Y; Bolze A; Chaldebas M; Milisavljevic B; Gervais A; Bastard P; Asano T; Bizien L; Barzaghi F; Abolhassani H; Abou Tayoun A; Aiuti A; Alavi Darazam I; Allende LM; Alonso-Arias R; Arias AA; Aytekin G; Bergman P; Bondesan S; Bryceson YT; Bustos IG; Cabrera-Marante O; Carcel S; Carrera P; Casari G; Chaïbi K; Colobran R; Condino-Neto A; Covill LE; Delmonte OM; El Zein L; Flores C; Gregersen PK; Gut M; Haerynck F; Halwani R; Hancerli S; Hammarström L; Hatipoğlu N; Karbuz A; Keles S; Kyheng C; Leon-Lopez R; Franco JL; Mansouri D; Martinez-Picado J; Metin Akcan O; Migeotte I; Morange PE; Morelle G; Martin-Nalda A; Novelli G; Novelli A; Ozcelik T; Palabiyik F; Pan-Hammarström Q; de Diego RP; Planas-Serra L; Pleguezuelo DE; Prando C; Pujol A; Reyes LF; Rivière JG; Rodriguez-Gallego C; Rojas J; Rovere-Querini P; Schlüter A; Shahrooei M; Sobh A; Soler-Palacin P; Tandjaoui-Lambiotte Y; Tipu I; Tresoldi C; Troya J; van de Beek D; Zatz M; Zawadzki P; Al-Muhsen SZ; Alosaimi MF; Alsohime FM; Baris-Feldman H; Butte MJ; Constantinescu SN; Cooper MA; Dalgard CL; Fellay J; Heath JR; Lau YL; Lifton RP; Maniatis T; Mogensen TH; von Bernuth H; Lermine A; Vidaud M; Boland A; Deleuze JF; Nussbaum R; Kahn-Kirby A; Mentre F; Tubiana S; Gorochov G; Tubach F; Hausfater P; ; ; ; ; ; ; ; ; ; Meyts I; Zhang SY; Puel A; Notarangelo LD; Boisson-Dupuis S; Su HC; Boisson B; Jouanguy E; Casanova JL; Zhang Q; Abel L; Cobat A
Genome Med; 2023 Apr; 15(1):22. PubMed ID: 37020259
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
Shi D; Chen J; Zhao M; Tang Y; Zhao C; Jin Y; Tian D; Liao Y; Wang X; Wang W; Fan X; Yi Z; Chen X; Ling Y
J Clin Immunol; 2024 Mar; 44(3):80. PubMed ID: 38462559
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.
Wang X; Tang Q; Li H; Jiang H; Xu J; Bergquist R; Qin Z
Int J Infect Dis; 2023 May; 130():147-152. PubMed ID: 36907547
[TBL] [Abstract][Full Text] [Related]
11. Differential interferon-α subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection.
Schuhenn J; Meister TL; Todt D; Bracht T; Schork K; Billaud JN; Elsner C; Heinen N; Karakoese Z; Haid S; Kumar S; Brunotte L; Eisenacher M; Di Y; Lew J; Falzarano D; Chen J; Yuan Z; Pietschmann T; Wiegmann B; Uebner H; Taube C; Le-Trilling VTK; Trilling M; Krawczyk A; Ludwig S; Sitek B; Steinmann E; Dittmer U; Lavender KJ; Sutter K; Pfaender S
Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35131898
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
[TBL] [Abstract][Full Text] [Related]
13. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α.
Mathian A; Breillat P; Dorgham K; Bastard P; Charre C; Lhote R; Quentric P; Moyon Q; Mariaggi AA; Mouries-Martin S; Mellot C; Anna F; Haroche J; Cohen-Aubart F; Sterlin D; Zahr N; Gervais A; Le Voyer T; Bizien L; Amiot Q; Pha M; Hié M; Chasset F; Yssel H; Miyara M; Charneau P; Ghillani-Dalbin P; Casanova JL; Rozenberg F; Amoura Z; Gorochov G
Ann Rheum Dis; 2022 Dec; 81(12):1695-1703. PubMed ID: 35973806
[TBL] [Abstract][Full Text] [Related]
14. High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals.
Prokop JW; Hartog NL; Chesla D; Faber W; Love CP; Karam R; Abualkheir N; Feldmann B; Teng L; McBride T; Leimanis ML; English BK; Holsworth A; Frisch A; Bauss J; Kalpage N; Derbedrossian A; Pinti RM; Hale N; Mills J; Eby A; VanSickle EA; Pageau SC; Shankar R; Chen B; Carcillo JA; Sanfilippo D; Olivero R; Bupp CP; Rajasekaran S
Front Immunol; 2021; 12():694243. PubMed ID: 34335605
[TBL] [Abstract][Full Text] [Related]
15. Human genetics of SARS-CoV-2 infection and critical COVID-19.
Mogensen TH
Clin Microbiol Infect; 2022 Nov; 28(11):1417-1421. PubMed ID: 35218979
[TBL] [Abstract][Full Text] [Related]
16. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
18. Infection-induced inflammation from specific inborn errors of immunity to COVID-19.
Ku CL; Chen IT; Lai MZ
FEBS J; 2021 Sep; 288(17):5021-5041. PubMed ID: 33971084
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
20. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease.
Busnadiego I; Abela IA; Frey PM; Hofmaenner DA; Scheier TC; Schuepbach RA; Buehler PK; Brugger SD; Hale BG
PLoS Biol; 2022 Jul; 20(7):e3001709. PubMed ID: 35788562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
